CureVac GmbH - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'CureVac GmbH - Product Pipeline Review - 2016', provides an overview of the CureVac GmbH's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by CureVac GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of CureVac GmbH - The report provides overview of CureVac GmbH including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses CureVac GmbH's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features CureVac GmbH's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate CureVac GmbH's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for CureVac GmbH - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding CureVac GmbH's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Content 2 List of Tables 5 List of Figures 5 CureVac GmbH Snapshot 6 CureVac GmbH Overview 6 Key Information 6 Key Facts 6 CureVac GmbH - Research and Development Overview 7 Key Therapeutic Areas 7 CureVac GmbH - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Pipeline Products - Out-Licensed Products 14 Out-Licensed Products/Combination Treatment Modalities 15 CureVac GmbH - Pipeline Products Glance 16 CureVac GmbH - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 CureVac GmbH - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 CureVac GmbH - Drug Profiles 20 CV-9104 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 CV-9103 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 CV-9201 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 CV-8102 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 nadorameran 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Oligonucleotide for Cancer 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Oligonucleotide for Infectious Disease 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Oligonucleotide for Influenza Virus Infection 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Oligonucleotide for respiratory syncytial virus vaccine 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 infectious disease vaccine 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Oligonucleotide for HIV 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Oligonucleotide for Respiratory Syncytial Virus-1 Infection 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Oligonucleotide for Rotavirus Infection 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Oligonucleotide for Undisclosed Indication 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Oligonucleotides for Undisclosed Indication 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Vaccine 1 for oncology 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Vaccine for Oncology 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 CureVac GmbH - Pipeline Analysis 40 CureVac GmbH - Pipeline Products by Target 40 CureVac GmbH - Pipeline Products by Route of Administration 41 CureVac GmbH - Pipeline Products by Molecule Type 42 CureVac GmbH - Recent Pipeline Updates 43 CureVac GmbH - Dormant Projects 46 CureVac GmbH - Locations And Subsidiaries 47 Head Office 47 Other Locations & Subsidiaries 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49
List of Tables
CureVac GmbH, Key Information 6 CureVac GmbH, Key Facts 6 CureVac GmbH - Pipeline by Indication, 2016 9 CureVac GmbH - Pipeline by Stage of Development, 2016 10 CureVac GmbH - Monotherapy Products in Pipeline, 2016 11 CureVac GmbH - Partnered Products in Pipeline, 2016 12 CureVac GmbH - Partnered Products/ Combination Treatment Modalities, 2016 13 CureVac GmbH - Out-Licensed Products in Pipeline, 2016 14 CureVac GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016 15 CureVac GmbH - Phase II, 2016 16 CureVac GmbH - Phase I, 2016 17 CureVac GmbH - Preclinical, 2016 18 CureVac GmbH - Discovery, 2016 19 CureVac GmbH - Pipeline by Target, 2016 40 CureVac GmbH - Pipeline by Route of Administration, 2016 41 CureVac GmbH - Pipeline by Molecule Type, 2016 42 CureVac GmbH - Recent Pipeline Updates, 2016 43 CureVac GmbH - Dormant Developmental Projects,2016 46 CureVac GmbH, Other Locations 47
List of Figures
CureVac GmbH - Pipeline by Top 10 Indication, 2016 8 CureVac GmbH - Pipeline by Stage of Development, 2016 10 CureVac GmbH - Monotherapy Products in Pipeline, 2016 11 CureVac GmbH - Out-Licensed Products in Pipeline, 2016 14 CureVac GmbH - Pipeline by Top 10 Target, 2016 40 CureVac GmbH - Pipeline by Route of Administration, 2016 41 CureVac GmbH - Pipeline by Molecule Type, 2016 42
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the markeRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive tRead More...
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.